JP2013544797A5 - - Google Patents

Download PDF

Info

Publication number
JP2013544797A5
JP2013544797A5 JP2013534982A JP2013534982A JP2013544797A5 JP 2013544797 A5 JP2013544797 A5 JP 2013544797A5 JP 2013534982 A JP2013534982 A JP 2013534982A JP 2013534982 A JP2013534982 A JP 2013534982A JP 2013544797 A5 JP2013544797 A5 JP 2013544797A5
Authority
JP
Japan
Prior art keywords
compound
salt
alkyl
group
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013534982A
Other languages
English (en)
Japanese (ja)
Other versions
JP5769326B2 (ja
JP2013544797A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/056505 external-priority patent/WO2012054367A1/en
Publication of JP2013544797A publication Critical patent/JP2013544797A/ja
Publication of JP2013544797A5 publication Critical patent/JP2013544797A5/ja
Application granted granted Critical
Publication of JP5769326B2 publication Critical patent/JP5769326B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013534982A 2010-10-19 2011-10-17 Rhoキナーゼ阻害薬 Active JP5769326B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39441410P 2010-10-19 2010-10-19
US61/394,414 2010-10-19
PCT/US2011/056505 WO2012054367A1 (en) 2010-10-19 2011-10-17 Rho kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2013544797A JP2013544797A (ja) 2013-12-19
JP2013544797A5 true JP2013544797A5 (enExample) 2014-12-04
JP5769326B2 JP5769326B2 (ja) 2015-08-26

Family

ID=44898209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013534982A Active JP5769326B2 (ja) 2010-10-19 2011-10-17 Rhoキナーゼ阻害薬

Country Status (4)

Country Link
US (1) US9000154B2 (enExample)
EP (1) EP2630144B1 (enExample)
JP (1) JP5769326B2 (enExample)
WO (1) WO2012054367A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9000154B2 (en) 2010-10-19 2015-04-07 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9499553B2 (en) 2013-03-13 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
JP6434968B2 (ja) 2013-07-02 2018-12-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Rock阻害剤としての三環式ピリド−カルボキサミド誘導体
WO2015002926A1 (en) * 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
JP6779214B2 (ja) * 2015-01-09 2020-11-04 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Rock阻害剤としての環状ウレア
EP3294871B1 (en) 2015-05-12 2026-04-29 HemostOD SA Combination of pharmacological and microfluidic features for improved platelets production
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210208A (en) 1990-09-24 1993-05-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
JPH11130751A (ja) 1997-10-30 1999-05-18 Yoshitomi Pharmaceut Ind Ltd アミド化合物およびそれらの酸付加塩の標識化合物
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
RU2251419C2 (ru) * 2000-06-21 2005-05-10 Ф. Хоффманн-Ля Рош Аг Производные бензотиазола
AU2002225767A1 (en) 2000-11-28 2002-06-11 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2003321472A (ja) * 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk阻害剤
US20040186151A1 (en) 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
WO2004076420A1 (ja) * 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
US20070010529A1 (en) * 2003-05-19 2007-01-11 Kanji Takahashi Nitrogenous heterocyclic compounds and medical use thereof
FR2862965B1 (fr) 2003-11-27 2007-09-07 Merck Sante Sas Nouveaux derives de phenoxyacetamides et leur utilisation pour la preparation de diphenylamides.
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US20080009477A1 (en) 2004-11-04 2008-01-10 Neurogen Corporation Arylalkyl Ureas As Cb1 Antagonists
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
ES2580108T3 (es) 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
EP2526948A1 (en) 2006-09-20 2012-11-28 Aerie Pharmaceuticals, Inc. RHO kinase inhibitors
WO2008053319A1 (en) 2006-10-30 2008-05-08 Pfizer Products Inc. Amide resorcinol compounds
ES2627221T3 (es) 2006-12-28 2017-07-27 Rigel Pharmaceuticals, Inc. Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso
CL2007003874A1 (es) * 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
WO2008157330A1 (en) 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
US8445686B2 (en) 2007-08-27 2013-05-21 Abbvie Inc. 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
WO2009028543A1 (ja) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 置換ピラゾール誘導体
EP2231600B1 (en) 2007-11-16 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
US20090270361A1 (en) 2008-03-26 2009-10-29 Takeda Pharmaceutical Company Limited Substituted pyrazole derivatives and use thereof
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9000154B2 (en) 2010-10-19 2015-04-07 Boehringer Ingelheim International Gmbh Rho kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2013531013A5 (enExample)
JP2013530237A5 (enExample)
JP2018507877A5 (enExample)
JP2017509586A5 (enExample)
JP5366968B2 (ja) Dna中のg−四重鎖領域と相互作用するナフタレンジイミド化合物
JP2016505010A5 (enExample)
JP2021515773A5 (enExample)
JP2019518766A5 (enExample)
JP2010536761A5 (enExample)
JP2016505042A5 (enExample)
JP2020502049A5 (enExample)
JP2016510033A5 (enExample)
JP2012502890A5 (enExample)
JP2012502111A5 (enExample)
JP2017525737A5 (enExample)
JP2014139226A5 (enExample)
JP2016503786A5 (enExample)
JP2010504908A5 (enExample)
JP2016518328A5 (enExample)
JP2012515209A5 (enExample)
JP2016540749A5 (enExample)
JP2019502763A5 (enExample)
JP2020517598A5 (enExample)
JP2005516067A5 (enExample)
JP2018522033A5 (enExample)